Japan-multimodal intervention trial for the prevention of dementia in older people with lifestyle-related diseases: A community-based,18-month,randomized controlled trial
Restricted accessResearch articleFirst published online July, 2025
Japan-multimodal intervention trial for the prevention of dementia in older people with lifestyle-related diseases: A community-based,18-month,randomized controlled trial
The prevalence of Alzheimer's disease is increasing in Japan, highlighting the need to establish evidence-based strategies for its prevention.
Objective
We aimed to evaluate the effectiveness of a multimodal community-based intervention for Japanese older people with lifestyle-related diseases and to identify challenges in implementing such interventions to prevent dementia in local communities.
Methods
An 18-month randomized controlled trial was conducted among individuals aged 65–85 years with lifestyle-related diseases (hypertension, hyperlipidemia, diabetes, overweight/underweight, smoking), residing in a single apartment complex. Participants were randomly assigned to a multimodal intervention group (group-based physical exercise, nutritional guidance, management of lifestyle-related diseases, and cognitive training) or a control group. The primary outcome was the change in the composite score derived from seven neuropsychological tests. The trial was registered (UMIN000041887: September 24, 2020).
Results
Of 224 screened individuals, 198 were randomized (99 in each group), and 175 (88.4%) completed the 18-month assessment. There was no significant difference between the intervention and control groups in the primary outcome (change in composite test score: 0.25; 95% confidence interval 0.16 to 0.33 versus 0.29; 95% confidence interval 0.20 to 0.38, respectively; p= 0.463). However, a subgroup analysis of participants with mild cognitive impairment showed a significant intervention effect on changes in logical memory, for both immediate (p = 0.041) and delayed recall tasks (p= 0.043).
Conclusions
This multimodal intervention program demonstrated no effectiveness in mitigating cognitive decline. Further research is needed to develop more effective strategies and to better define target populations.
PrinceMWimoAGuerchetM, et al.World Alzheimer report 2015. The global impact of dementia: an analysis of prevalence, incidence, cost and trends. London, England: Alzheimer’s Disease International, 2015.
2.
NicholsESteinmetzJDVollsetSE, et al.Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health2022; 7: e105–e125.
3.
CummingsJZhouYLeeG, et al.Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement (N Y)2023; 9: e12385.
4.
LivingstonGHuntleyJSommerladA, et al.The lancet commissions dementia prevention, intervention, and care: 2020 report of the lancet commission. Lancet2020; 396: 413–459.
5.
McGrathERBeiserASDeCarliC, et al.Blood pressure from mid-to late life and risk of incident dementia. Neurology2017; 89: 2447–2454.
6.
AnsteyKJAshby-MitchellKPetersR. Updating the evidence on the association between serum cholesterol and risk of late-life dementia: review and meta-analysis. J Alzheimers Dis2017; 56: 215–228.
7.
KopfDFrölichL. Risk of incident Alzheimer’s disease in diabetic patients: a systematic review of prospective trials. J Alzheimers Dis2009; 16: 677685.
8.
AlbaneseELaunerLJEggerM, et al.Body mass index in midlife and dementia: systematic review and meta-regression analysis of 589,649 men and women followed in longitudinal studies. Alzheimers Dement (Amst)2017; 8: 165–178.
9.
AnsteyKJvon SandenCSalimA, et al.Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol2007; 166: 367–378.
10.
TomSEHubbardRACranePK, et al.Characterization of dementia and Alzheimer’s disease in an older population: updated incidence and life expectancy with and without dementia. Am J Public Health2015; 105: 408–413.
11.
NganduTLehtisaloJSolomonA, et al.A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet2015; 385: 2255–2263.
12.
RosenbergANganduTRusanenM, et al.Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: the FINGER trial. Alzheimers Dement2018; 14: 263–270.
13.
KivipeltoMMangialascheFSnyderHM, et al.World-Wide FINGERS network: a global approach to risk reduction and prevention of dementia. Alzheimers Dement2020; 16: 1078–1094.
14.
SugimotoTSakuraiTAkatsuH, et al.The Japan-multimodal intervention trial for prevention of dementia (J-MINT): the study protocol for an 18-month, multicenter, randomized, controlled trial. J Prev Alzheimers Dis2021; 8: 465–476.
15.
AraiHSugimotoTAkatsuH, et al.The Japan-multimodal intervention trial for prevention of dementia (J-MINT): a multi-center, randomized, 18-month controlled trial. Alzheimers Dement2023; 19(S24): e082704.
16.
SakuraiTSugimotoTAkatsuH, et al.Japan-Multimodal Intervention trial for the prevention of dementia: a randomized controlled trial. Alzheimers Dement2024; 20: 3918–3930.
17.
OnoRKowaHOkiY, et al.Baseline characteristics in Japan-multimodal intervention trial for prevention of dementia (J-MINT) Tamba study. Alzheimers Dement2021; 17(S10): e053802.
18.
KumagaiROsakiTOkiY, et al.The Japan-multimodal intervention trial for prevention of dementia PRIME Tamba (J-MINT PRIME Tamba): study protocol of a randomised controlled multi-domain intervention trial. Arch Gerontol Geriatr2023; 104: 104803.
19.
Ministry of Health, Labour and Welfare of Japan, 2020. The dietary reference intakes for Japanese, 2020. https://www.mhlw.go.jp/stf/newpage_08517. Html (last updated 24 December 2019, accessed 29 November 2020).
20.
FolsteinMFFolsteinSEMcHughPR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
21.
ItoH. Committee report: glycemic targets for elderly patients with diabetes. J Diabetes Investig2017; 8: 126–128.
22.
UmemuraSArimaHArimaS, et al.The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res2019; 42: 1235–1481.
23.
KinoshitaMYokoteKAraiH, et al.Japan Atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb2018; 25: 846–984.
24.
YokoyamaYNishiMMurayamaH, et al.Association of dietary variety with body composition and physical function in community-dwelling elderly Japanese. J Nutr Health Aging2016; 20: 691–696.
25.
OtsukaRNishitaYTangeC, et al.Dietary diversity decreases the risk of cognitive decline among Japanese older adults. Geriatr Gerontol Int2017; 17: 937–944.
26.
ScarmeasNAnastasiouCAYannakouliaM. Nutrition and prevention of cognitive impairment. Lancet Neurol2018; 17: 1006–1015.
27.
OtsukaRTangeCNishitaY, et al.Serum docosahexaenoic and eicosapentaenoic acid and risk of cognitive decline over 10 years among elderly Japanese. Eur J Clin Nutr2014; 68: 503–509.
28.
OzawaMOharaTNinomiyaT, et al.Milk and dairy consumption and risk of dementia in an elderly Japanese population: the Hisayama study. J Am Geriatr Soc2014; 62: 1224–1230.
29.
OtsukaRKatoYNishitaY, et al.Cereal intake increases and dairy products decrease risk of cognitive decline among elderly female Japanese. J Prev Alzheimers Dis2014; 1: 160–167.
30.
TomataYSugiyamaKKaihoY, et al.Green tea consumption and the risk of incident dementia in elderly Japanese: the ohsaki cohort 2006 study. Am J Geriatr Psychiatry2016; 24: 881–889.
31.
WechslerD. Wechsler memory scale-revised. San Antonio, TX: Psychological Corporation, 1981.
32.
GroberEBuschkeHKoreySR. Genuine memory deficits in dementia. Dev Neuropsychol1987; 3: 13–36.
33.
WechslerD. Manual for the Wechsler adult intelligence scale. New York: Psychological Corporation, 1955.
34.
LezakMDHowiesonDBLoringDW. Neuropsychological assessment. 4th ed.New York: Oxford University Press, 2004.
35.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
36.
MahonyFIBarthelDW. Functional evaluation: the Barthel Index. Md State Med J1965; 14: 61–65.
37.
LawtonMPBrodyEM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist1969; 9(3_Part_1): 179–186.
38.
FriedLPTangenCMWalstonJ, et al.Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci2001; 56: M146–M157.
39.
MakizakoHShimadaHTsutsumimotoK, et al.Social frailty in community-dwelling older adults as a risk factor for disability. J Am Med Dir Assoc2015; 16: 1003.e7–1003.e11.
40.
TanakaTHiranoHOharaY, et al.Oral frailty Index-8 in the risk assessment of new-onset oral frailty and functional disability among community-dwelling older adults. Arch Gerontol Geriatr2021; 94: 104340.
41.
KimuraYWadaTIshineM, et al.Food diversity is closely associated with activities of daily living, depression, and quality of life in community-dwelling elderly people. J Am Geriatr Soc2009; 57: 922–924.
42.
RubensteinLZHarkerJOSalvàA, et al.Screening for undernutrition in geriatric practice: developing the short-form Mini-nutritional assessment (MNA-SF). Gerontol A Biol Sci Med Sci2001; 56: M366–M372.
43.
WilsonMMGThomasDRRubensteinLZ, et al.Appetite assessment: simple appetite questionnaire predicts weight loss in community-dwelling adults and nursing home residents. Am J Clin Nutr2005; 82: 1074–1081.
44.
YesavageJABrinkTLRoseTL, et al.Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res1982; 17: 37–49.
45.
KikuchiRKozakiKIwataA, et al.Evaluation of risk of falls in patients at a memory impairment outpatient clinic. Hypertens Res2009; 9: 298–303.
46.
LubbenJBlozikEGillmannG, et al.Performance of an abbreviated version of the lubben social network scale among three European community-dwelling older adult populations. Gerontologist2006; 46: 503–513.
47.
KunzS. Psychometric properties of the EQ-5D in a study of people with mild to moderate dementia. Qual Life Res2010; 19: 425–434.
48.
BuysseDJReynoldsCFMonkTH, et al.The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res1989; 28: 193–213.
49.
KanamoriSKaiYAidaJ, et al.Social participation and the prevention of functional disability in older Japanese: the JAGES cohort study. PLoS One2014; 9: e99638.
50.
CassarlyCMatthewsLJSimpsonAN, et al.The revised hearing handicap inventory and screening tool based on psychometric reevaluation of the hearing handicap inventories for the elderly and adults. Ear Hear2018; 41: 95–105.
51.
ShimadaHMakizakoHParkH, et al.Validity of the national center for geriatrics and gerontology-functional assessment tool and Mini-mental state examination for detecting the incidence of dementia. Geriatr Gerontol Int2017; 17: 2383–2388.
52.
MakizakoHShimadaHParkH, et al.Evaluation of multidimensional neurocognitive function using a tablet personal computer: test–retest reliability and validity in community-dwelling older adults. Geriatr Gerontol Int2013; 13: 860–866.
53.
AndrieuSGuyonnetSColeyN, et al.Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol2017; 16: 377–389.
54.
ShimadaHMakizakoHDoiT, et al.Effects of combined physical and cognitive exercises on cognition and mobility in patients with mild cognitive impairment: a randomized clinical trial. J Am Med Dir Assoc2018; 19: 584–591.
55.
AndrieuSColeyNLovestoneS, et al.Prevention of sporadic Alzheimer’s disease: lessons learned from clinical trials and future directions. Lancet Neurol2015; 14: 926–970.
56.
OliveiraFFAlmeidaSSChenES, et al.Pharmacogenetics of angiotensin modulators according to APOE-ε4 alleles and the ACE insertion/deletion polymorphism in Alzheimer's disease. Acta Neuropsychiatr2023; 35: 346–361.
57.
OliveiraFFBertolucciPHFChenES, et al.Pharmacogenetic analyses of therapeutic effects of lipophilic statins on cognitive and functional changes in Alzheimer's disease. J Alzheimers Dis2022; 87: 359–372.
58.
OliveiraFFChenESSmithMC, et al.Selected LDLR and APOE polymorphisms affect cognitive and functional response to lipophilic statins in Alzheimer's disease. J Mol Neurosci2020; 70: 1574–1588.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
